Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1645
This examiner grants 52% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18051468 | TREATMENT OF OSTEOGENESIS IMPERFECTA | Non-Final OA | Genzyme Corporation |
| 17350898 | IL-10-CONTAINING VACCINES AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18833541 | BIFIDOBACTERIUM BREVE FOR IMPROVING AGING-RELATED COGNITIVE DISORDER AND USE THEREOF | Final Rejection | WECARE PROBIOTICS CO., LTD. |
| 18879356 | NOVEL BIFIDOBACTERIUM BREVE JKL2022 STRAIN AND METHOD FOR PRODUCING CONJUGATED LINOLEIC ACID USING THEREOF | Non-Final OA | CHUNG ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION |
| 18097461 | BACILLUS SP. PRODUCING BIOFLOCCULANT AND BIOSURFACTANT AND USE THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18685422 | DEVELOPMENT OF SYNTHETIC PSEUDAMINIC ACID-BASED ANTIBACTERIAL VACCINES AGAINST ACINETOBACTER BAUMANNII | Non-Final OA | City University of Hong Kong |
| 18548987 | LATERAL FLOW ASSAY FOR DETECTING PATHOGENS IN MILK FROM MASTITIC COWS | Non-Final OA | Zoetis Services LLC |
| 18627462 | PHARMACEUTICAL COMPOSITION FOR ALLEVIATIONN, TREATMENT, AND PREVENTION OF SARCOPENIA CONTAINING MICROORGANISM TRANSFORMED WITH CELL SURFACE DISPLAY VECTOR OPERABLY LINKED WITH GENE ENCODING MYOSTATIN AND ACTIVIN A PROTEINS AS ACTIVE INGREDIENT | Non-Final OA | MOALIFEPLUS CO., LTD. |
| 18688067 | COMPOSITIONS COMPRISING BACILLUS AMYLOLIQUEFACIENS FOR PREVENTING AND TREATING ULCERATIVE COLITIS | Non-Final OA | Artugen Therapeutics Ltd. |
| 18254754 | STABILISED LACTIC ACID BACTERIA COMPOSITIONS | Non-Final OA | Chr. Hansen A/S |
| 17628667 | QUANTIFICATION OF BIOCONJUGATE GLYCOSYLATION | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18504114 | MITIGATION OF PATHOGENS IN PORCINE SPECIES | Non-Final OA | Purina Animal Nutrition LLC |
| 18551954 | NOVEL RECOMBINANT STRAIN OF MYCOBACTERIUM SMEGMATIS AND USE OF SAME | Non-Final OA | CLIPSBNC CO., LTD. |
| 17911524 | COMBINED CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD20 AND APPLICATIONS THEREOF | Non-Final OA | AbelZeta Inc. |
| 18055177 | RECOMBINANT GAS VESICLE NANOPARTICLES | Non-Final OA | PUKYONG NATIONAL UNIVERSITY INDUSTRY UNIVERSITY COOPERATION FOUNDATION |
| 17791859 | TGFB INHIBITORS AND USE THEREOF | Non-Final OA | Scholar Rock, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy